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Background: Exacerbations of chronic obstructive pulmonary disease (COPD) are sporadic, acute worsening of
symptoms. Identifying predictors of exacerbation frequency may facilitate medical interventions that reduce
exacerbation frequency and severity. The objective of this study was to determine predictors of exacerbation
frequency and mortality.
Methods: A total of 227 COPD patients were enrolled in a prospective clinical study between January 2000 and
December 2011. Reported exacerbations were recorded for the year preceding enrollment and annually thereafter,
and patients were grouped by median annual exacerbation frequency into those experiencing infrequent
exacerbations (less than one exacerbation annually) and frequent exacerbations (one or more exacerbation
annually). Patients experiencing frequent exacerbations were further divided into those experiencing moderately
frequent exacerbations (fewer than two exacerbations per year) and severely frequent exacerbations (two or more
exacerbations per year). The rate of clinical relapse and survival was recorded over a 10-year period. The mean of
follow-up time was 5.15 years per patient.
Results: For patients experiencing infrequent, moderately frequent, and severely frequent exacerbations, median
exacerbations in the year preceding enrollment were 0.0, 0.5, 1.0, respectively, and more frequent exacerbations
correlated with lower baseline forced expiratory volume in one second (FEV1) (0.81 L, 0.75 L, and 0.66 L,
respectively), higher comorbidity (70.7%, 75.0%, and 89.4%, respectively), and greater NPPV use during
hospitalization (16.4%, 35.9% and 51.1%, respectively). FEV1 declined and mortality increased with increasing
exacerbation frequency.
Conclusions: Exacerbation frequency can be used to generate discreet patient subpopulations, supporting the
hypothesis that multiple COPD phenotypes exist and can be used in patient risk stratification.
Keywords: Chronic obstructive pulmonary disease, Exacerbation, Forced expiratory volume, Comorbidity, Positive
pressure ventilationBackground
Chronic obstructive pulmonary disease (COPD), charac-
terized by difficulty breathing due to chronic bronchitis
or emphysema, is one of the most common lung condi-
tions observed in clinical practice, the fourth leading
cause of death in the world [1]. An exacerbation of
COPD is defined as acute worsening in the severity of a* Correspondence: tongzhh2012@163.com
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reproduction in any medium, provided the orpatient’s symptoms, including baseline dyspnea and cough,
that warrants a change in medication or medical inter-
vention [2]. Exacerbations have been linked to disease-
associated morbidity and mortality, placing significant
strain on medical facilities, increasing resource burden,
and driving up ongoing healthcare costs [3]. To better al-
locate healthcare resources, exacerbations can be classified
by symptom type and severity, and by the frequency of in-
cidents requiring intervention [4].
Exacerbation frequency varies significantly among pa-
tients [5,6], and more frequent exacerbations are linked
to more rapidly declining lung function and higher mor-
tality [5]. The importance of exacerbation prediction hasd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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and aggressive prevention strategies [3], including anti-
biotic therapies that are designed to reduce exacerbation
frequency and severity [7]. While major advances have
been made in the past decade, measureable prognostic
factors predicting exacerbation risk in COPD patients
remain undefined.
The most reliable predictor of increasing exacerbation
frequency is conventionally considered to be a patient’s
previous history of exacerbations [8], potentially indicat-
ing a definable phenotype of exacerbation susceptibility.
Most published research on COPD exacerbations are
large interventional studies [9,10] with highly variable
exacerbation definitions [8-10]. Thus, few data have
been collected that can reliably indicate clinically meas-
urable prognostic risk factors for COPD exacerbation
frequency and associated clinical outcomes.
To better assess the prognostic factors associated with
COPD frequency, we followed a 227-member cohort
of COPD patients over a 10-year period. We identi-
fied predictors of exacerbation frequency and gener-
ated a mechanism for improved clinical classification of
COPD patients by exacerbation frequency. This classifi-
cation may improve the efficacy of strategically applied
prophylactic interventions.Methods
Study design and patient groups
A total of 227 COPD patients were recruited consecu-
tively between 1 January 2000 and 31 December 2006
for inclusion in a study of exacerbation frequency ran-
ging from the inclusion start date to 31 December 2011
at the Outpatient Department of Respiration of the
Shougang Hospital of Beijing University (Beijing, China).
The study protocol was approved by the Medical ethics
committee of Shou-Gang Hospital Affiliated to Peking
University. All patients provided written informed con-
sent for participation.Inclusion and exclusion criteria
Inclusion criteria included a COPD diagnosis, defined as
a forced expiratory volume in 1 second (FEV1) of < 80%
of the predicted value after bronchodilator use and a ra-
tio of FEV1 to forced vital capacity (FVC) of < 70% after
bronchodilator use. We recruited participants between
the ages of 45 and 85 years who were in a stable condi-
tion, having experienced no exacerbations in the month
preceding enrollment, and who could provide medical
records indicating the number of times in the preceding
year they had been hospitalizations as a result of COPD.
Patients who did not consent to long-term follow-up or
were diagnosed with another condition that limited life
expectancy were excluded from the analysis.Exacerbations
We defined an exacerbation as sustained worsening of
respiratory symptoms, such as breathlessness or in-
creased sputum volume or purulence beyond the basal
variability and that required treatment with oral cortico-
steroids or antibiotics [11,12]. In this study we recorded
only those exacerbations resulting in hospitalization, and
exacerbations separated by ≥ 14 days were considered
distinct events [13-16]. Reported exacerbations were re-
corded for the year preceding enrollment, and annually
thereafter until the end of the study or death. Patients
were grouped by the median annual exacerbation fre-
quency into those experiencing infrequent exacerbations
(Group 1: less than one exacerbation annually) and frequent
exacerbations (Group 2: one or more exacerbation annu-
ally). Patients experiencing frequent exacerbations were fur-
ther divided into those experiencing moderately frequent
exacerbations (Group 2A: fewer than two exacerbations per
year) and severely frequent exacerbations (Group 2B: two or
more exacerbations per year) (Figure 1).
Data collection and follow-up
During initial clinical examinations, patient demographics
were recorded, including sex, age, height, weight, body
mass index (BMI), and smoking history. Clinical charac-
teristics were recorded for each patient, including lung
function, drug history (including bronchial-dilating agents,
glucocorticoids), comorbidities, number of hospitalization
as a result of COPD exacerbations in the year preced-
ing enrollment, and every year throughout the follow-
up period, and use of long-term oxygen therapy (LTOT),
home mechanical ventilation (HMV) used for chronic hy-
percapnia of COPD, and non-invasive positive pressure
ventilation (NPPV, used for exacerbations accompanied by
acute respiratory failure) during hospitalization. Follow-up
was conducted by telephone interview and review of ap-
propriate medical records every 6 months until the end of
the study. Quint et al. have previously determined that pa-
tient recall was a sufficiently accurate tool for stratification
of patients into those experiencing frequent and infre-
quent exacerbations [16].
Lung function was assessed using a volumetric stor-
age spirometer (HP 47-804; Hewlett-Packard, Waltham,
MA, USA) to measure arterial carbon dioxide tension
(PaCO2); arterial oxygen tension (PaO2); forced expiratory
volume in one second (FEV1); and forced vital capacity
(FVC) at baseline (year 0) and thereafter at 2-year inter-
vals for the first 4 years. GOLD grades were calculated ac-
cording to the Global Initiative for Chronic Obstructive
Lung Disease.
At the end of follow-up, the Charlson comorbidity
index was computed and analyzed. The Charlson Index
assigns a score to each underlying condition proportional
to its corresponding disease-related risk of death [17]. The
Figure 1 Flow diagram of study design and patient grouping.
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was used as an index for each patient.
Statistical analysis
Statistical analyses were performed using SPSS version
17.0 (SPSS Inc., Chicago, IL, USA). Continuous variables
were presented as means ± standard deviation (SD) or as
medians and interquartile ranges by data distribution.
One-way ANOVA was used to compare exacerbation fre-
quency. Chi-square tests with Pearson’s, continuity correc-
tion, or Fisher’s Exact test were used for binary variables.
Logistic regression analysis was used to identify independ-
ent predictors of frequent exacerbations. Univariate sur-
vival analysis was performed using Kaplan-Meier analysis
(log-rank test). Multivariate COX proportional hazards
regression models were used to identify independentpredictors of mortality. Relative risk and 95% confidence
intervals (CIs) were presented. P values less than 0.05
were considered statistically significant.
Results
Clinical and demographic characteristics
A total of 227 patients were enrolled. The mean age of
participants was 71.7 ± 6.8 years, and ranged from 45
to 85 years. Of these participants, 70% were male. Pa-
tients were grouped by the median annual exacerbation
frequency. A total of 51.1% (116/227) of the patients expe-
rienced infrequent exacerbations (less than one exacerba-
tion annually) and were assigned to Group 1, and 48.9%
(111/227) experienced frequent exacerbations (one or
more exacerbations annually) were assigned to Group 2.
Patients experiencing frequent exacerbations were further
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(64/227) experienced moderately frequent exacerbations
(fewer than two exacerbations per year) and were assigned
to Group 2A. Another 20.1% (47/227) experienced se-
verely frequent exacerbations (two or more exacerbations
per year) and were assigned to Group 2B (Table 1).Table 1 Baseline of clinical and demographic characteristics a
Parameters Group 1 (n = 116)
Age (mean ± SD, yrs) 71.78 ± 6.36
Male, % 73.3
Height (mean ± SD, cm) 169.6 ± 2.32
Weight (mean ± SD, kg) 67.06 ± 4.10
BMI (mean ± SD, kg/m2) 23.58 ± 3.31
Current smoker, % 56.0
Numbers of preceding year exacerbationa 0 (0 to 1.0)
GOLD grade
GOLD 1, % 4.3
GOLD 2, % 16.4
GOLD 3, % 45.7
GOLD 4, % 33.6
FEV1 (mean ± SD, L)
b 0.81 ± 0.36
FEV1 (mean ± SD, % predicted) 38.76 ± 16.90
FVC, (mean ± SD, L)c 1.50 ± 0.54
pH (mean ± SD) 7.40 ± 0.04
PaCO2 (mean ± SD, mmHg)
d 48.03 ± 9.97
PaO2 (mean ± SD, mmHg) 67.42 ± 11.67
Cor pulmonale, %e 34.5
Comorbidity, %f 70.7
Cardiovascular disease, % (n) 62.9 (73)
Cerebrovascular disease, % (n) 28.4 (33)
Diabetes mellitus, % (n) 14.7 (17)
Neoplasms, % (n) 7.8 (9)
Osteoporosis, % (n) 2.6 (3)
Arrhythmia, % (n) 2.6 (3)
Total comorbidity 1 (0 to 3.0)
Charlson index (mean ± SD)g 5.30 ± 1.77
Medicine at home, % 29.3
LTOT at home, % 6.9
HMV, % 1.7
NPPV in hospitalization, %*h 16.4
BMI, body mass index; FEV1, forced expiratory volume in one second; FVC, forced v
treatment; NPPV, non-invasive positive pressure ventilation; PaCO2, arterial carbon d
a:Pgroup 1-group 2B and Pgroup 1-group 2A < 0.001;
b:Pgroup 1-group 2B = 0.012;
c:Pgroup 1-group 2B = 0.013;
d:Pgroup 1-group 2B = 0.044;
e:Pgroup 1-group 2A = 0.008; and Pgroup 1-group2B = 0.001;
f:Pgroup 1-group 2B = 0.011;
g:Pgroup 1-group2B = 0.014;
h:Pgroup 1-group 2A = 0.003; and Pgroup 1-group 2B < 0.001.The mean follow-up time was 5.15 years per pa-
tient. The number of exacerbations in the year be-
fore recruitment into this study, FEV1, FVC, PaCO2,
cor pulmonale, comorbidity, and the Charlson Index
score of patients varied significantly between groups
(P < 0.05, Table 1).mong groups according to exacerbation frequency
Group 2A (n = 64) Group 2B (n = 47) Total (n = 227)
71.02 ± 7.24 72.19 ± 7.30 71.65 ± 6.80
67.2 66.0 70.0
171.2 ± 3.19 170.7 ± 2.56 170.9 ± 3.03
67.60 ± 3.78 71.20 ± 3.98 68.90 ± 2.75
23.05 ± 4.30 24.42 ± 3.68 23.60 ± 3.70
57.8 66.0 58.6






0.75 ± 0.33 0.66 ± 0.29 0.76 ± 0.34-
37.61 ± 17.08 34.49 ± 11.91 37.55 ± 16.07-
1.42 ± 0.49 1.27 ± 0.53 1.43 ± 0.53-
7.40 ± 0.04 7.40 ± 0.04 7.40 ± 0.04-
51.35 ± 10.45 49.78 ± 12.04 49.33- ± 10.61
67.10 ± 14.30 65.56 ± 13.01 66.94 ± 12.70-
54.7 63.8 46.3-
75.0 89.4 75.8-
79.7 (51) 74.5 (35) 70.0 (159) -
23.4 (15) 36.2 (17) 28.6 (65) -
14.1 (9) 12.8 (6) 14.1 (32) -
7.8 (5) 10.6 (5) 8.4 (19) -
3.1 (2) 4.3 (2) 3.1 (7) -
1.6 (1) 4.3 (2) 2.6 (7) -
1 (0 to 4.0) 1 (0 to 3.6) 1 (1.0-2.0) -





ital capacity; HMV, home mechanical ventilation; LTOT, long-term oxygen
ioxide tension; PaO2, arterial oxygen tension.
Figure 3 GOLD (Global Initiative for Chronic Obstructive Lung
Disease) grades of COPD patients in Group 1, 2A and 2B,
experiencing infrequent, mildly frequent and severely frequent
exacerbations respectively.
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More frequent exacerbations were significantly associ-
ated with lower FEV1 and FVC, a higher frequency of
exacerbation in the preceding year, higher PaCO2,
higher incidence of cor pulmonale, and a higher rate
of comorbidities (P < 0.05, Table 1). The most common
comorbidity was cardiovascular disease, though cere-
brovascular disease, diabetes mellitus, and neoplasm
were also observed.
Scoring assessments indicate exacerbation frequency
Significantly higher Charlson Index scores were ob-
served in Group 2B than in both Group 1 and Group
2A (P = 0.014, Figure 2). There was no significant differ-
ence in GOLD grades between the three groups (P > 0.05,
Figure 3). All GOLD grades were represented in each
group, with the exception that Group 2b contained no pa-
tients with a Gold grade of 1. For GOLD grades 1 to 3, the
number of exacerbations increased significantly in all
three groups (P < 0.05, Figure 3). Notably, patients with a
GOLD grade of 4 experienced a significantly lower fre-
quency of exacerbations than patients with a GOLD grade
of 3 (P < 0.05, Figure 3).
Comorbidity and exacerbation frequency
The proportion of comorbidities in patients assigned a
GOLD grade of 4 was significantly lower that of patients
with GOLD grades 1, 2 and 3 (63.8% versus 100%, 82.8%
and 80.7%, respectively, all P < 0.05). Increased exacerba-
tion frequency was significantly associated with higher
rates of comorbidities (P < 0.05, Table 2).
The rate of NPPV use by GOLD 4 patients (40.8%) was
significantly higher than the rate of NPPV use by GOLD 3
(28.4%) or GOLD 2 (10.3%) patients (all P < 0.05). NPPV
use in Group 2A (35.9%) and Group 2B (51.1%) was sig-
nificantly higher than NPPV use in Group 1 (16.4%, ORFigure 2 Comparison of Charlson Index among COPD patients
in Groups 1, 2A and 2B, experiencing infrequent, mildly
frequent and severely frequent exacerbations respectively.
Note: pgroup 1-group2B = 0.014.2.864, 95% CI 1.410 to 5.819, and OR 5.327, 95% CI 2.507
to 11.326, respectively, Table 2). Increased exacerbation
frequency was significantly associated with higher levels of
NPPV use (P < 0.05, Table 2).
Forced expiratory volume in one second is related to
exacerbation frequency
Logistic analysis revealed that increased exacerbation
frequency was significantly associated with worsening
lung function, measured by post-bronchodilator FEV1
(P < 0.05, Table 2). Over the 4 years of follow-up, the
FEV1 of patients in Group 2A and 2B declined faster
than in Group 1, with the most notable decline occurring
in the last 2 years (Figure 4A). Patients in Group 2B expe-
rienced consistent decline over the 4 years, compared with
Group 2A patients, who experienced more rapid declineTable 2 Logistic analysis of predictors for severely
frequent exacerbations (Group 2B)
B Wald Sig. RR 95% CI for RR
Lower Upper
Comorbidity 1.340 5.453 0.020 3.818 1.240 11.752
NPPV 1.145 7.691 0.006 3.143 1.399 7.062




0.861 13.881 0.000 2.366 1.504 3.722
RR, relative risk; NPPV, non-invasive positive pressure ventilation; FEV1, forced
expiratory volume in one second.
AB
Figure 4 Change in FEV1. FEV1 (A) in patients experiencing
infrequent (Group 1) and frequent exacerbations (Group 2, including
Group 2A and Group 2B) and (B) and those experiencing mildly
frequent exacerbations (Group 2A) and severely frequent
exacerbations (Groups 2B) over time.
Figure 5 Survival by year in COPD patient group 1, 2A and 2B,
experiencing infrequent, mildly frequent and severely frequent
exacerbations respectively. Note: Pgroup 1 – group 2 = 0.026, Pgroup 1
– group 2B = 0.009, Pgroup 2 A– group 2B = 0.561.
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creet stages of disease progression. Overall, FEV1 was re-
duced in Groups 1, 2A, and 2B by an average of 38 mL,
46 mL, and 44.6 mL per year respectively, representing no
significant variation between groups (P > 0.05).
Exacerbation history is related to exacerbation frequency
A history of previous exacerbations was also signifi-
cantly associated with increased exacerbation frequency
(P < 0.05, Table 2).Mortality increases with increasing exacerbation
frequency
A total of 135 (59.5%) patients died during the follow-up
window, and 2 (0.01%) patients were lost to follow-up. By
the endpoint of the study, the overall mortality was 50.0%,
in Group 1, 67.2%, in Group 2A, and 72.3% in Group 2B,
but did not differ significantly between the three groups.
The cumulative survival time of Group 1 was significantly
longer than that of Group 2A and 2B, but did not differ
significantly between Group 2A and 2B (Figure 5).
Deaths were due to respiratory failure (51.1%), comor-
bidities (46.7%), and unknown factors (2.2%). Of those
deaths related to comorbidities (63 in total), 38.1% were
related to infections, 25.4% were related to neoplasms,
including lung cancer (62.5%), cerebrovascular disease
(15.9%), cardiovascular disease (14.3%), and pulmonary
embolism (6.3%).
Patients in Group 2B and 2A had mortality rates ap-
proximately 2.6 fold and 2.0 fold greater, respectively,
than patients in Group 1 (95% CI 1.253 to 5.457; 95% CI
1.084 to 3.868). Significantly different 5- and 10-year cu-
mulative survival rates were observed in Groups 1 (58%
and 41%), 2A (58% and 41%) and 2B (29% and 23%) (P =
0.003, Table 1). More patients in Group 1 died as a result
of a comorbidity than respiratory failure (51.7% versus
39.7%), whereas the majority of patients in group 2A died
of respiratory failure (60.5% versus 34.9%). Patients in
Group 2B died of respiratory failure and comorbidities at
a similar rate (50.0% versus 44.1%).
Verifying the prognostic factors for mortality
COX analysis by age, sex, smoking, BMI, PH, PaCO2,
PaO2, FEV1, FEV1%, FVC, cor pulmonale, comorbidity,
Table 3 Cox analysis of independent prognostic factors
for all chronic obstructive pulmonary disease (COPD)
patients
Items B Wald Sig. RR 95.0% CI for RR
Lower Upper
Exacerbation frequency 0.418 11.868 0.001 1.518 1.197 1.926
FEV1% predicted −0.015 4.412 0.036 0.985 0.972 0.999
Charlson Index 0.201 7.311 0.007 1.222 1.057 1.413
Age 0.034 4.147 0.042 1.035 1.001 1.070
NPPV −0.664 8.578 0.003 0.515 0.330 0.803
PaCO2 0.022 4.373 0.037 1.023 1.001 1.044
Cor pulmonale 0.390 3.988 0.046 1.477 1.007 2.165
BMI −0.087 11.383 0.001 0.917 0.872 0.964
Total comorbidities −0.297 7.790 0.005 0.743 0.603 0.915
RR, relative risk; FEV1, forced expiratory volume in one second; NPPV, non-invasive
positive pressure ventilation; PaCO2, arterial carbon dioxide tension; BMI, body
mass index.
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tions in the year preceding the study and exacerba-
tion frequency preceding enrollment provided verification
that higher rates of exacerbation frequency in the past
are an independent prognostic factor of exacerbation
frequency in the future (Table 3). In addition to vari-
able exacerbation frequency, this analysis also indi-
cated that FEV1, age, cor pulmonale, BMI, Charlson
Index, total comorbidities, and NPPV use were also
independent prognostic factors for exacerbation fre-
quency (Table 3). However, as NPPV is administrated
during the hospitalization for acute exacerbation of
chronic obstructive pulmonary disease with acute re-
spiratory failure, increased frequency of acute exacer-
bation resulted in increased administration of NPPV,
and NPPV is not a predictor of acute exacerbation
frequency.
Discussion
A group of COPD patients that were susceptible to mul-
tiple exacerbations was identified and the associations
between these occurrences and potential prognostic fac-
tors including FEV1, exacerbation history, NPPV use,
and comorbidities were determined. Logistic analysis of
exacerbation frequency during a follow-up period con-
firmed that the rate of exacerbations reported in the year
preceding enrollment was an independent predictor of
more frequent exacerbations in the future. Patients with
moderately frequent and severely frequent exacerbations
had mortality rates approximately 2.6 fold and 2.0 fold
greater, respectively, than those experiencing infrequent
exacerbations, and COX analysis confirmed that exacer-
bation frequency was an independent prognostic factor
for elevated mortality. These findings highlight the need
for improved identification and stratification of COPDpatients with frequent exacerbations for more in-depth
monitoring and treatment with more aggressive thera-
peutic strategies.
The study of COPD exacerbations is complicated by
the varying definition of exacerbations employed. Studies
have applied a variety of cutoffs related to the median
number of exacerbations per study group [3,13,18], a
relative measurement that makes it difficult to compare
data between studies. In an attempt to mediate these
discrepancies, some studies have applied a fixed model
for assessing exacerbation frequency, wherein ‘frequent
exacerbations’ are defined as those occurring two or
more times a year [10,19]. This model was applied in
this study, and additionally, we specified that the exacer-
bation events must be separated by 14 days and require
hospitalization.
Several models for the prediction of COPD exacerba-
tions have been explored over the past decade. Hurst
et al. [6] reported that a reliable predictor of exacerba-
tions across all GOLD stages was a previous history of
exacerbations. Numerous additional studies have con-
firmed that previous COPD exacerbations are a risk fac-
tor for new exacerbations, independent of COPD
severity and other clinical manifestations [3,5,7,8]. Simi-
larly, within the population we studied, exacerbation fre-
quency preceding enrollment was found to be an
independent predictor of exacerbation frequency during
the follow-up period.
We have identified some additional prognostic factors
that can be used to stratify COPD patient risk; FEV1, co-
morbidities, and NPPV use, along with exacerbation his-
tory, were identified as independent predictors of
elevated exacerbation frequency. Similarly, the TORCH
(Toward a Revolution in COPD Health) trial [20] re-
ported a negative association between exacerbation fre-
quency and declining FEV1, and David et al. reported
that higher exacerbation frequency was associated with
significantly lower baseline post-bronchodilator FEV1.
Conversely, Kirby et al. [21] determined that FEV1 was
not a significant clinical predictor of frequent exacerba-
tions. We can conclude that the number of exacerba-
tions does not increase linearly with FEV1 decline, but is
influenced by multiple factors.
Clinical manifestations of systemic inflammation are
often observed in parallel with COPD exacerbations
[22]. Extra-pulmonary factors may play a role in COPD-
related declining lung function. As reported for cardio-
vascular exacerbations, patients with higher numbers of
concomitant disorders may be more prone to exacerba-
tions leading to frequent hospitalization [23]. These find-
ings were confirmed in a case–control study of severe
COPD patients that indicated patients with frequent exac-
erbations also experienced more frequent cardiovascular
comorbidities [24], consistent with the elevated rate of
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tients experiencing frequent exacerbations in this study.
However, because these observations were not found to
be statistically significant, further study will be required to
verify this association.
While this report identifies the association between
several prognostic factors and increased exacerbation
frequency in COPD patients, further study is required
before broad clinical recommendations can be made.
Conclusions
A history of frequent exacerbations, lower FEV1, and
multiple comorbidities were independent prognostic fac-
tors for exacerbation frequency, in a 10-year study of 227
COPD patients. Patients who experienced two or more
exacerbations annually were at a greater risk for early
mortality than patients with less frequent exacerbations.
Thus, these patients should be considered candidates for
aggressive monitoring and therapy to mediate COPD dis-
ease progression and to reduce exacerbation frequency
and severity. Furthermore, the stratification of patients in
this study supports the hypothesis that discreet pheno-
types exist that can be used to determine patient risk in
clinical settings.
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